Chimerix Announces Commencement of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- Copart nears $2B all-cash deal to acquire ACV Auctions - Bloomberg
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Chimerix (CMRX) Prices 3.78M Offering at $39.75/Share
June 11, 2015 6:53 AM EDTChimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $39.75 per share. The gross... More
Chimerix (CMRX) to Commence $150M Common Stock Offering
June 9, 2015 4:32 PM EDTChimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to offer and sell, subject to market and other conditions, approximately $150.0 million of its common stock in an underwritten public offering.... More
